Figure 4.

Effect of AAV-sTRAIL vector on U87 glioma tumors. (a,b) 5 × 10⁴ U87 glioma cells expressing Fluc, a marker for tumor volume, were implanted in the brain of nude mice. Fourteen days later, mice were randomized into two groups and infused into the same tumor injection site with either AAV-Vluc/GFP or AAV-Vluc/sTRAIL (n = 5/group). Mice were imaged for Fluc at days 2, 7, 14, and 21 after vector injection. (a) Representative set of mice from each group are shown. Note that the scale is different for each time point in order to show the tumor site. (b) Quantitation of brain tumor-associated Fluc signal in mice over time. The arrow indicates that all mice in the AAV-Vluc/GFP group were sacrificed between week 2 and week 3 due to tumor burden (*P = 0.048 at day14 and *P = 0.0008 at day 21). (c) Survival analysis of mice bearing U87 glioma tumors treated with either AAV-Vluc/GFP or AAV-Vluc/sTRAIL (n = 5; P = 0.0088). All Graphs are generated from a representative data set of three independent experiments.